{"nctId":"NCT02398188","briefTitle":"Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)","startDateStruct":{"date":"2015-04-09","type":"ACTUAL"},"conditions":["Central Abdominal Bulging"],"count":793,"armGroups":[{"label":"LIPO-202","type":"EXPERIMENTAL","interventionNames":["Drug: LIPO-202"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"LIPO-202","otherNames":["Salmeterol"]},{"name":"Placebo","otherNames":["Placebo for LIPO-202"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy male or non-pregnant female subjects\n* Capable of providing written consent.\n* BMI \\< 30 kg/m2\n* Stable diet and exercise routine\n* Central abdominal bulging that is evaluated by the clinician at least slight bulge, not flat\n\nExclusion Criteria:\n\n* Have had any treatment of the fat around your abdomen, including surgical procedures (tummy tuck, liposuction), injections for fat loss or treatments with devices to reduce fat in your abdomen.\n* Plan on starting a weight loss or exercise program during the study.\n* Known hypersensitivity to study drugs","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Who Achieved a Composite P-GAPS1/CPnS2 Response","description":"The composite P-GAPS1/CPnS2 response was defined as at least a 1 point (grade) improvement in P-GAPS and at least a 2 point (grade) improvement in CPnS from baseline after 8 weeks of treatment.\n\nPatient - Global Abdominal Perception Scale (P-GAPS) - a patient views and assesses the contour of their abdomen on a 5-point verbal scale ranging from \"Flat\" to \"Big Bulge\".\n\nClinician Photonumeric Scale (CPnS) - a trained clinician rater examines the subject's abdomen and matches the subject's abdominal bulge/profile to the nearest gender-specific abdominal photo on the 6-point scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"PRIMARY","title":"Percent Change in the Patient Reported Global Abdominal Perception Score","description":"1 equals much improved, 7 equals much worse. The higher the scores the worse the outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"202","spread":"51"},{"groupId":"OG001","value":"175","spread":"44"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Waist Circumference","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","spread":"2.65"},{"groupId":"OG001","value":"24.2","spread":"2.66"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":398},"commonTop":["Injection Site Bruising","Injection Site Haemorrhage","Injection Site Pain","Upper Respiratory Tract Infection","Injection Site Erythema"]}}}